+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2026-2032- Product Image
GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2026-2032- Product Image
New

GalNAc-Oligonucleotide Conjugates Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 189 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6120806
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The GalNAc-oligonucleotide conjugates market is advancing toward an execution-focused era, where quality, durability, and supply chain resilience are vital for long-term differentiation. As this modality integrates deeper into clinical and commercial strategies, decision-makers must address evolving technical, regulatory, and geopolitical requirements.

Market Snapshot: GalNAc-Oligonucleotide Conjugates Market Overview

The GalNAc-oligonucleotide conjugates market grew from USD 416.37 million in 2025 to USD 454.35 million in 2026, and is projected to reach USD 685.84 million by 2032, experiencing a robust CAGR of 7.38%. Senior stakeholders across the biopharma value chain are accelerating platform adoption and operationalizing best practices to optimize scalability and compliance in diverse regional landscapes.

Scope & Segmentation

  • Product Types: Includes siRNA-based conjugates and antisense oligonucleotide conjugates, each representing distinct development philosophies and platform choices.
  • Chemistry Approaches: Features triantennary GalNAc architectures, innovative linker chemistries, and variable molecular designs influencing potency, tolerability, and manufacturability.
  • Applications: Targets rare genetic diseases, cardiometabolic conditions, and infectious disease-adjacent liver disorders. Adoption patterns depend on genetic causality, cohort characteristics, and evidence requirements.
  • End Users: Segmentation includes pharmaceutical innovators, biotechnology firms, academic/research institutes, and contract development and manufacturing organizations (CDMOs).
  • Distribution Channels: Examines direct procurement models as well as specialized distributors, each impacting supply continuity and documentation standards.
  • Geographic Regions: Analysis covers the Americas, Europe, Middle East & Africa, and Asia-Pacific, highlighting unique regulatory, manufacturing, and adoption dynamics.

Key Takeaways for Senior Decision-Makers

  • GalNAc-oligonucleotide conjugates are now a foundational technology for targeted delivery to hepatocytes, enabling more consistent and effective therapeutic programs.
  • Scientific advances in conjugation chemistry increase analytical and manufacturing expectations, driving a marketplace where operational maturity is as critical as technical ingenuity.
  • Competitive pressure is moving downstream into CMC rigor, emphasizing the need for robust impurity management, process adaptability, and platform-standardized analytical methods.
  • Manufacturing network strategies are evolving toward hybrid and regionalized models, ensuring continuity and strategic control over critical supply steps.
  • Stakeholder familiarity with infrequent dosing and biomarker-led monitoring is enabling new lifecycle strategies, including earlier label expansion planning and combination regimens.

Tariff Impact: Navigating Supply Chain Resilience in 2025

Anticipated United States tariff actions in 2025 are prompting procurement and CMC teams to re-examine the origin and qualification of critical inputs. Organizations are segmenting material criticality, pre-approving alternative suppliers, and investing in regionally integrated manufacturing footprints to insulate against procurement volatility and longer lead times. Any shift in supplier or process, driven by trade pressures, demands a careful balance with regulatory comparability and quality expectations. This environment will reward companies adept at converting trade uncertainties into structured supply resilience with minimal project disruption.

Methodology & Data Sources

This report blends a rigorous review of secondary sources—such as peer-reviewed literature, regulatory publications, patent filings, clinical registries, and industry announcements—with primary insights from R&D leaders, CMC specialists, supply chain managers, quality professionals, and clinicians. The triangulated approach ensures signals are validated, avoiding over-reliance on single perspectives and supporting actionable strategic planning.

Why This Report Matters

  • Enables portfolio and pipeline decision-makers to benchmark operational practices against industry leaders across technology, sourcing, and regulatory segments.
  • Supports risk mitigation by mapping critical supply chain vulnerabilities and offering clear strategies for navigating emerging policy and regulatory dynamics.
  • Facilitates internal alignment by delivering concise, evidence-driven insights for executive management, operational teams, and investor stakeholders.

Conclusion

As the GalNAc-oligonucleotide conjugates market matures, leaders that standardize platform governance, proactively manage supply chains, and link CMC choices to clinical and commercial realities will be best positioned to excel. Strategic execution and integrated policy-aware planning will set durable competitors apart in this evolving sector.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. GalNAc-Oligonucleotide Conjugates Market, by Product Type
8.1. Antisense Oligonucleotides
8.2. Aptamers
8.3. MiRNA
8.4. SiRNA
9. GalNAc-Oligonucleotide Conjugates Market, by Therapeutic Application
9.1. Infectious Diseases
9.2. Metabolic Disorders
9.3. Oncology
9.4. Rare Diseases
10. GalNAc-Oligonucleotide Conjugates Market, by Route of Administration
10.1. Intravenous
10.2. Subcutaneous
10.2.1. Clinical Stage
10.2.2. Preclinical Stage
11. GalNAc-Oligonucleotide Conjugates Market, by End User
11.1. Biotechnology Companies
11.2. Contract Research Organizations
11.3. Pharmaceutical Companies
11.3.1. Large Pharma
11.3.2. Small Pharma
12. GalNAc-Oligonucleotide Conjugates Market, by Distribution Channel
12.1. Direct Sales
12.2. Distributors
12.3. Offline
12.4. Online
13. GalNAc-Oligonucleotide Conjugates Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. GalNAc-Oligonucleotide Conjugates Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. GalNAc-Oligonucleotide Conjugates Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States GalNAc-Oligonucleotide Conjugates Market
17. China GalNAc-Oligonucleotide Conjugates Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Akcea Therapeutics, Inc.
18.6. Alnylam Pharmaceuticals, Inc.
18.7. Amgen Inc.
18.8. Arcturus Therapeutics Holdings Inc.
18.9. Arrowhead Pharmaceuticals, Inc.
18.10. AstraZeneca plc
18.11. Beam Therapeutics Inc.
18.12. BioNTech SE
18.13. CureVac N.V.
18.14. Eli Lilly and Company
18.15. Gilead Sciences, Inc.
18.16. GlaxoSmithKline plc
18.17. Ionis Pharmaceuticals, Inc.
18.18. Merck & Co., Inc.
18.19. Moderna, Inc.
18.20. Novartis AG
18.21. Novo Nordisk A/S
18.22. Pfizer Inc.
18.23. Regeneron Pharmaceuticals, Inc.
18.24. Roche Holding AG
18.25. Sanofi S.A.
18.26. Sarepta Therapeutics, Inc.
18.27. Takeda Development Center Americas, Inc.
18.28. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY APTAMERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY MIRNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY MIRNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY MIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRECLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRECLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRECLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SMALL PHARMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SMALL PHARMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SMALL PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 105. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 110. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 112. EUROPE GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 123. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 124. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 126. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 128. AFRICA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 140. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 141. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 143. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 145. ASEAN GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 148. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 149. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 151. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 153. GCC GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 156. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 157. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 162. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 164. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 165. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 167. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 169. BRICS GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 172. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 173. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 175. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 177. G7 GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 179. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 180. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 183. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 184. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 185. NATO GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 189. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 190. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 191. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 192. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 194. UNITED STATES GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 196. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 197. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
TABLE 198. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, 2018-2032 (USD MILLION)
TABLE 200. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
TABLE 202. CHINA GALNAC-OLIGONUCLEOTIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this GalNAc-Oligonucleotide Conjugates market report include:
  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CureVac N.V.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Takeda Development Center Americas, Inc.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages189
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 454.35 Million
Forecasted Market Value ( USD ) by 2032 $ 685.84 Million
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Reports

GalNac Conjugates Market - Global Forecast 2025-2030 - Product Image

GalNac Conjugates Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
GalNAc-ASO Conjugates Market - Global Forecast 2026-2032 - Product Image

GalNAc-ASO Conjugates Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
RNAi Therapeutics Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

RNAi Therapeutics Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 87 Pages
  • Global
From
RNA Interference- Pipeline Insight, 2025 - Product Image

RNA Interference- Pipeline Insight, 2025

  • Drug Pipelines
  • 204 Pages
  • Global
From
Alpha-1 Antitrypsin Deficiency- Pipeline Insight, 2025 - Product Image

Alpha-1 Antitrypsin Deficiency- Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.